Allergic conjunctivitis is one of the most common eye conditions. A new large-scale genetic study shows that susceptibility to the disease is strongly linked to genes that regulate inflammation and ...

His parents believe his death was due to a coronary artery rupture, as his heart vessels were damaged when he had Kawasaki disease at seven months old. They want to raise awareness of the disease, ...

Dry eye disease affects millions of people, causing burning, redness, and constant eye fatigue that can worsen over time. Scientists now believe the problem may begin deep inside tear glands, where a ...

Dec 31 (Reuters) - Outlook Therapeutics (OTLK.O), opens new tab said on Wednesday the U.S. health regulator has declined to approve its drug for a type of eye disease, dealing another blow in the ...

Twenty-two percent of African-American adults ages 40 and older with eye disease in a cross-sectional study had undetected eye disease. Diabetic retinopathy (82%) and age-related macular degeneration ...

Please provide your email address to receive an email when new articles are posted on . The TFOS DEWS III report compiles the last 8 years of research into the diagnosis and management of dry eye ...

A strain of H5N1 avian influenza virus found in a Texas dairy worker who was infected this spring was able to spread among ferrets through the air, although inefficiently, and killed 100% of infected ...

(RTTNews) - Argenx SE (ARGX ARGX.BR) announced on Monday that it is discontinuing its Phase 3 UplighTED studies evaluating Efgartigimod PH20 SC in adults with moderate to severe thyroid eye disease, ...

While argenx has been able to demonstrate the merit of its FcRn drug Vyvgart in multiple autoimmune indications, not every shot in the clinic is destined to land. Now, facing that fact in thyroid eye ...

Argenx SE shares fell the most in seven months after the biotech firm said it will discontinue late-stage trials for an experimental medicine to treat an autoimmune disease affecting the eyes.

Dec 1 (Reuters) - Belite Bio (BLTE.O), opens new tab said on Monday that its experimental drug for a rare genetic eye disease met the main goal in a late-stage study, sending its shares up over 15% in ...